annals of oncology: TNBCDX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

Redefining precision oncology

Unlocking the full potential of patient information

We want to change how biomarkers are routinely used in oncology

Separator

Analyze
the Past

Analyzing
complex genomic
and clinical data

Separator

Decode
the present

Decoding biomarkers before,
during or after therapies
using different biopsy-based approaches

Separator

Reveal
the future

Revealing innovative tests of
high analytical complexity,
but easy-to-interpret results

Learn more
HER2DX packaging

The first genomic tool for patients with
HER2+ breast cancer

HER2DX® is intended to help select the optimal treatment strategy for patients.

REVEAL GENOMICS® and HER2DX® are registered trademarks of REVEAL GENOMICS S.L.
Learn More Order HER2DX®

New

REPORT

Image of the four pages of the HER2DX report
HER2DX score bar
Icon of time meaning the most recent

Updated version with the most recent studies conducted on HER2DX®.

Icon of bars meaning more visual results

More visual results, the scores are shown in representation with their scale.

Icon of guide meaning extensive description

Extensive description and guidance for reading the results, their clinical significance and supporting data.

Graphic bars meaning interpretation of results

Extensive explanation
of the scores for a better interpretation of the results.

DOWNLOAD A SAMPLE REPORT

PRESS RELEASE

REVEAL GENOMICS® Unveils TNBCDX®: the First Genomic Test Designed for Early-stage Triple-Negative Breast Cancer

BLOG

We continue to gather more support data for HER2DX®